Genmab — Februar 2024
-
-
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY
) for Difficult-to https://www.proinvestor.com/investornyt/1123507/us-fda-accepts-for-priority-review-the-supplemental-biologics-license-application-for-epcoritamab-epkinly-for-difficult-to -
Godmorgen
-
Genmab får godkendt ansøgning om hastebehandling af kræftmiddel hos FDA https://www.proinvestor.com/investornyt/1123555/genmab-far-godkendt-ansogning-om-hastebehandling-af-kraeftmiddel-hos-fda
-
Genmab ejer 1,24 pct. egne aktier. Selskabet har opkøbt egne aktier for 168,3 mio. kr. ud af et samlet aktietilbagekøbsprogram , der afsluttes 15. marts 2024.
-
Morn
Bliver nok svært at snakke kursen op uanset om det er positiv eller negativ snak. Tror bare man skal komme Genmab i skuffen til H2 og så ellers nyde det gode vejr samt der er andre investeringer i porteføljen der trækker op. Trods alt sjældent at alt i en differentieret pulje stiger samtidigt. -
Så nyd sommeren og så vender vi kajakken i H2. https://www.youtube.com/watch?v=RR5jDkfVtp8
-
Genmabs fornuftige regnskab ligner vendepunktet
David Mygind
Mandag 26. februar 2024 https://ugebrev.dk/life-science/genmabs-fornuftige-regnskab-ligner-vendepunktet/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind